Ad-Lib.io Adds Spain to International Roster of Teams With Google Marketing Partner Creative Certifications
Ad-Lib.io, the next-generation Creative Management Platform for marketers at the world’s largest brands, today announced that it has been certified as a Google Marketing Platform (GMP) Partner in Spain, bringing Ad-Lib.io its sixth creative certification as it continues to extend its footprint across the globe.
The GMP Creative Certification in Spain affirms that Ad-Lib.io has demonstrated the ability to work within Google’s best practices and technology, and reinforces that its next-generation Creative Management Platform upholds high standards of service for creative design and process management. The certification reaffirms Ad-Lib.io’s successful client track record and its expertise across key capabilities including coding, asset delivery, and client services. The certification gives Ad-Lib.io , early access to product releases and announcements, and to a variety of other Google program resources.
“As the advertising industry emerges from a difficult year, advertisers are pushed to make their creative workflow more efficient while ensuring their ads stand out and perform well,” said Adit Abhyankar, CEO of Ad-Lib.io. “As a Google Marketing Platform Partner certified on the Creative tools, Ad-Lib.io offers advertisers in Spain on Google’s tech stack, the ability to easily and quickly build and activate content at scale, across formats and channels. Ad-Lib.io has been a trusted Google Partner since our founding in 2017 and we will continue to lead the way for advertisers that seek to produce and optimize relevant creative at scale.”
“As Google and its customers continue to find new ways to work together, partners like Ad-Lib.io are an important part of our ecosystem as they got certified.” according to Jose Maria Perez Sastre, Partnerships Manager at Google. “We are pleased that Ad-Lib.io continues to grow its presence and customers in Spain. We have seen great success already working together on clients in the region and we look forward to the continuing partnership in Spain and in other markets around the globe.”
This milestone strengthens Ad-Lib.io’s capability for customers working with the Google Marketing Platform in Spain and globally, as marketers seek solution providers that operate in the markets they serve. One partner with multi-region certifications, Ad-Lib.io is also a GMP Creative Partner in the United Kingdom, the United States, Dubai, Australia and Singapore.
“I'm very excited by the launch of another Google-certified market in Spain!” said Oli Marlow Thomas, founder of Ad-Lib.io. “This accompanies the awesome news that Ad-Lib.io DE is now up and running with former Googler Felix Derkum leading the charge. Ad-Lib.io is pushing into all parts of Europe.”
For more information about Ad-Lib.io, please visit: https://www.ad-lib.io/.
Ad-Lib.io provides the leading next-generation Creative Management Platform for marketers at the world’s largest brands to enable them to scale their digital creative. Ad-Lib.io connects creative and media workflows using intelligent automation, making it easy and fast to produce and optimize relevant ad creative across all digital channels. These ads are 60% more cost-efficient to produce, according to Ad-Lib.io’s customers which include 10 of the top 30 global brands. The venture-backed company -- recognized as a 2021 Start Up of the Year by Campaign Magazine -- was founded by former Google executives who understood the need to close the wide gap between creative concepts and digital media execution. Ad-Lib.io is headquartered in London, UK with offices in North America, Asia, Australia, Europe and the Middle East.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
805 695 6524
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Blood Center of New Orleans Cooperates With Biolog-id to Enhance Visibility, Availability, and Traceability of Life-saving Blood Components21.6.2021 15:17:00 CEST | Press release
Biolog-id LLC, a developer and service provider of connected healthcare solutions, announced today its partnership with The Blood Center of New Orleans. Biolog-id’s cutting-edge technology will provide digital visibility to all platelet types in accordance with the new FDA bacterial risk control guidance. The biolog-id solution will support operational, distribution and planning decisions across the entire lifecycle of these strategically important products. The use of the biolog-id solution for the rare red blood cells inventory will streamline the management of this complex inventory, facilitating better internal cooperation and optimizing the fulfilment of customer orders. “We are firm believers in leveraging technology to improve the efficiency, quality, and safety of the blood supply,” said Billy Weales, President & CEO at The Blood Center. “Our cooperation with biolog-id allows us to achieve these goals with two of our most critical blood components – platelets and rare red blood
Sky Labs Finalizes Series B Round Successfully Planning to Take Over Global Markets21.6.2021 15:00:00 CEST | Press release
Attracting USD 20 million investment, Sky Labs (CEO: Jack Lee), a global health care start-up, finalized Series B Round successfully. The accumulated amount of investment Sky Labs has attracted is USD 30 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005004/en/ Sky Labs, a global health care start-up, finalizes Series B Round successfully attracting USD 20 million investment. The accumulated amount of investment is USD 30 million. Sky Labs developed CART-I, the world’s first AI-based ring-type heart monitoring platform. It consists of a ring-type wearable medical device and user’s application and medical professional’s web platform and enables atrial fibrillation patients to conduct monitoring when they are not in a hospital. In addition, the photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger to measure irregular pulse waves. The measured data are transmitted to a cloud platfo
Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the Significant Under-Diagnosis of Migraine21.6.2021 14:01:00 CEST | Press release
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today presented new epidemiology data on migraine from the State of Israel which indicate that socio-economic factors may contribute to underdiagnosis of migraine across society1. A retrospective study of migraine epidemiology in Southern Israel, supported by Teva and presented at the virtual 7th Congress of the European Academy of Neurology (EAN), found extreme variability in the prevalence of diagnosed patients with migraine across the geographic area studied. Prevalence rates were positively associated with the socio-economic status of the geographic area studied, suggesting that those living with migraine from less advantaged areas may find it harder to achieve an accurate diagnosis and thereby access appropriate therapy. “These findings are concerning not least because they suggest significant ‘migraine awareness inequity’ in this population,” said Professor Gal Ifergane, study investigator, practitioner, head of the Depart
New Data Supporting the Safety and Efficacy Profile of AJOVY® (fremanezumab) Shared at 7th European Academy of Neurology Congress21.6.2021 14:01:00 CEST | Press release
A new analysis presented by Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on AJOVY® (fremanezumab) injection for the preventive treatment of migraine, indicates to the European neurology community that the medicine has a positive safety profile in relation to risk of cardiovascular events. The data, drawn from an analysis of three published Phase 3 studies of fremanezumab and presented at the 7th Congress of the European Academy of Neurology (EAN), showed minimal changes in the heart rate and blood pressure of those patients studied over a 12 week period. 1 “As a CGRP inhibitor, fremanezumab has been shown to provide protection against migraine in suitable patients, and we remain focused on continued assessment of the safety profile of this therapy, particularly in relation to heart-related issues as it is believed CGRP itself acts as a ‘safeguard’ during cardiovascular ischemia and other events,” said Dr Joshua M. Cohen, Senior Director and Global Therapeutic Area Lead, Mi
Ezbob Introduces New SaaS Platform to Meet the Changing Landscape of Digital Banking21.6.2021 11:00:00 CEST | Press release
Ezbob Ltd., an innovator in customer acquisition technology for financial services, today announced the introduction of a new modular SaaS platform that addresses key trends in the sector. The company’s Ezbob Express™, focuses on three important needs: offering financial service providers the flexibility of filling gaps in their digital transformation strategies, enabling them to make more precise complex credit and risk decisions in real-time, and facilitating the growth of embedded finance. Ezbob’s new Express customer acquisition platform has a modular approach, enabling financial institutions with gaps in their digital channel to add the functionality needed to achieve a customised digital experience. The new modules include: UX & Process Design, Compliance & Authentication, Credit & Risk Decisioning and Product Recommender. Since its inception Ezbob has been providing digital onboarding services for many well-known financial institutions including Santander, NatWest, Metro Bank, P
Ambarella Expands Security AI Vision SoC Portfolio With Two New Families; Doubles Resolution to 32MP30 for 4K Multi-Imager Cameras With Advanced AI21.6.2021 11:00:00 CEST | Press release
Ambarella, Inc. (NASDAQ: AMBA), an AI vision silicon company, today announced the expansion of its AI vision SoC portfolio with the new CV5S and CV52S security families. Based on the CVflow® architecture and advanced 5nm process technology, the new SoCs support simultaneous 4K encoding and advanced AI processing in a single low-power design, which provides industry-leading edge AI SoC performance per watt. The CV5S family is ideal for security camera applications that require multiple sensors for 360-degree coverage, over a wide area and with a long range, such as outdoor city environments or large buildings. The CV52S family is designed for single-sensor security cameras with advanced AI performance that need to more clearly identify individuals or objects in a scene, including faces and license plate numbers over long distances, such as ITS traffic cameras. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005178/en/ Am
Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction21.6.2021 10:36:00 CEST | Press release
The European Commission has granted marketing authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer Ingelheim and Eli Lilly and Company have announced.The extension of the indication follows a positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) on 20 May 2021.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005298/en/ “Today’s approval provides an important new treatment option which can now help the millions of people in Europe living with symptomatic chronic heart failure with reduced ejection fraction,” said Faiez Zannad, M.D., Ph.D., EMPEROR Program clinical investigator and Emeritus Professor of Therapeutics at the University of Lorraine, France. “New treatment options such as empagliflozin can save lives and help people spend less time in the hospital and mor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom